Skip to main content

Table 4 Patient characteristics and their association with sputum culture conversion

From: Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada

  Sputum culture conversion
N = 31
No sputum culture conversion
N = 37
Univariate model Multivariate model
OR (95%CI) P value OR (95%CI) P value
Sex, female 23 (74.2%) 23 (62.2%) 1.75 (0.62–4.97) 0.293   
Age (years), median (IQR) 58 (50–67) 61 (44–47.5) 1.00 (0.97–1.03) 0.953   
Species/complex
 MAC 17 (54.8%) 20 (54.1%) 1.02 (0.38–2.73) 0.969   
M. abscessus 3 (9.7%) 10 (27%) 0.28 (0.76–22.23) 0.073 0.87 (0.18–4.28) 0.868
M. xenopi 6 (19.4%) 2 (5.4%) 4.12 (0.76–22.23) 0.099 9.50 (0.68–131.82) 0.094
 MAC/M. xenopi 1 (3.2%) 2 (5.4%)     
 Macrolide resistant MAC 2 (6.5%) 3 (8.1%) 0.76 (0.12–4.89) 0.774   
M. simiae 1 (3.2%) 0     
M. fortuitum 1 (3.2%) 0     
FC pattern 13 (35.1%) 13 (41.9%) 1.33 (0.50–3.56) 0.566   
Cavity 21 (67.7%) 23 (62.2%) 1.28 (0.47–3.49) 0.632   
AFB positive ever 30 (96.8%) 37 (100%) 3.69 (0.15–93.81) 0.791   
Total dose AK per bodyweight (g/kg), median (IQR)b 0.79 (0.55–2.29) 1.20 (0.74–2.09) 0.81 (0.55–1.18) 0.268 0.54 (0.26–1.10) 0.089
Weekly dose AK per bodyweight (mg/kg/week), median (IQR)a 26.09 (23.61–33.87) 27.03 (22.6–40.3) 0.98 (0.94–1.03) 0.438   
Months on AK, median  (IQR) 8 (4–18) 8 (6–15) 0.98 (0.94–1.02) 0.356   
Total dose AK (g), Median (IQR)c 46.8 (29.4–130.3) 60.3 (37.8–118.0) 1.00 (0.99–1.01) 0.725   
Surgery 19 (61.3%) 2 (5.4%) 27.7 (5.61–136.9) < 0.001 33.01 (4.79–227.27) < 0.001
  1. FC Fibrocavitary pattern, IQR Interquartile Range, MAC Mycobacterium avium Complex, AK Amikacin
  2. aOR represents risk associated with each increase of 1 mg/kg/week
  3. bOR represents risk associated with each increase of 1 g/kg total dose
  4. cOR represents risk associated with each increase of 1 g total dose